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Methods: Cerebrospinal fluid (CSF) collection, [C-11]Pittsburgh compound B (PiB) amyloid imag-
ing, and magnetic resonance imaging were acquired in 104 cognitively healthy adults enriched with
risk for sporadic AD. Image-derived cerebral b-amyloid (Ab) burden, measured concurrently and
longitudinally, was regressed on CSF measures of Ab, neural injury, and inflammation, as well as ra-
tios with Ab42. Linear mixed-effects regression was used to model the effect of the CSFmeasures that
predicted longitudinal brain amyloid accumulation on longitudinal cognitive decline, measured by
memory test scores.
Results: At baseline, Ab42/Ab40 and all CSF ratios to Ab42 were associated with PiB binding in AD-
vulnerable regions. Longitudinally, Ab42/Ab40 and ratios of total tau (t-tau), phosphorylated-tau (p-
tau), neurofilament light protein, and monocyte chemoattractant protein-1 to Ab42 were associated
with increased Ab deposition over 2 years, predominantly in lateral parietal and temporal cortex.
However, these CSF ratios were not significantly associated with cognitive decline, and the effect
seems to be largely driven by Ab42 in the denominator.
Discussion: These results corroborate previous findings that t-tau/Ab42 and p-tau/Ab42 are the stron-
gest candidate biomarkers during the preclinical time frame. They support a framework in which neu-
ral injury and amyloid deposition are likely occurring simultaneously. It may be that
neurodegenerative processes influence progressive amyloid accumulation, even in the preclinicaling patent for an magnetic resonance imaging pulse
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Although it is widely accepted that Alzheimer’s disease
(AD) pathology, including b-amyloid (Ab) deposition in
plaques and microvessels and tau pathology in the form of
neurofibrillary tangle formation, begins decades before
symptom onset [1–4], there is a paucity of longitudinal
research in the late mid-life time frame [1] necessary to
establish this effect empirically. Greater understanding of
biomarkers associated with these hallmark features of AD,
including tau and Ab proteins in cerebrospinal fluid (CSF)
and in-vivo neuroimaging measures of Ab burden, during
preclinical stages is important for early detection and future
treatment and prevention efforts [1,2,5].
The most widely accepted model of AD etiology proposes
that amyloid deposition in the brain is an early and critical
step in driving the pathophysiological processes of AD that
in turn initiate neurodegeneration, in the form of synaptic
failure and neuronal death, and eventual symptom manifesta-
tion [1,6,7]. Increasing evidence suggests that amyloid may
be necessary—although even this is contested by some
[8]—but not sufficient for developing AD [6,8–11]. Ab
may be neither the primary nor the only neurotoxin that
causes AD; but it is likely the key initiator of many
complex, often tau-dependent, pathologic changes in the
brain culminating in neurodegeneration years later [12]. In
accordance with this theory, recent in vitro and in vivo
work demonstrates a dynamic positive feed-forward mecha-
nism whereby Ab drives the disease pathway through tau,
and tau further increases Ab levels [13]. Ab imaging by itself
is not sufficient for a clinical prognosis in the preclinical time
frame, and it may be that the most promising AD biomarkers
will encompass multiple aspects of the disease, including
amyloid and tau-mediated neural injury.
Because of the molecular exchange of metabolites be-
tween the brain and CSF, CSF analytes reflect biochemical
and pathologic processes in the brain [5,14,15], thereby
providing means for examining multiple indicators of
disease processes occurring in the central nervous system.
CSF Ab and tau have high diagnostic accuracy for AD
[16], but their reliability for the detection of possible preclin-
ical AD is still unclear.
To examine features associated with spatial amyloid
binding and longitudinal accumulation in the preclinical
time frame, we conducted a multimodal study with Pitts-
burgh compound B (PiB) positron emission tomography
(PET) imaging and CSF biomarkers in a late middle-aged,
cognitively healthy sample enriched with the risk factorsof apolipoprotein E ε4 (APOE ε4) genotype and parental his-
tory of sporadic AD from the Wisconsin Registry for Alz-
heimer’s Prevention (WRAP; [17]). Our study had three
aims as follows: (1) investigate relationships between amy-
loid pathology in the brain and concurrent CSF biomarkers
associated with amyloid deposition, neuronal injury, and
inflammation; (2) determine whether CSF biomarker levels
at baseline lumbar puncture (LP) predict changes in PiB am-
yloid deposition over a subsequent 2-year period; and (3)
investigate relationships between CSF predictors of brain
Ab and longitudinal cognitive decline.
We hypothesized that CSF biomarkers of AD pathology
including amyloid burden (lower Ab42), tangle pathology
(elevated phosphorylated-tau [p-tau]), axonal injury
(elevated total-tau [t-tau] and neurofilament light protein
[NFL]), and microglial activation/inflammation (elevated
monocyte chemoattractant protein 1 [MCP-1] and chiti-
nase-3–like protein [YKL-40]) would be associated with
greater amyloid deposition at baseline and greater longitudi-
nal amyloid accumulation over 2 years. We further hypoth-
esized that Ab42 ratios (e.g., t-tau/Ab42) would most likely
be associated with cognitive decline, as ratios reflect multi-
ple AD-related pathologies simultaneously, suggesting
greater risk for imminent disease.2. Material and methods
Extended materials and methods are included as
Supplementary Material.2.1. Participants
Participants in this study were recruited from WRAP
[17] if they had participated in biomarkers substudies.
For this analysis, subjects were included if they had one
or more amyloid and magnetic resonance imaging (MRI)
scans, and CSF collected at the time of the first amyloid
scan, resulting in a sample of 104. The University of Wis-
consin Institutional Review Board approved all study pro-
cedures, and each subject provided signed informed
consent before participation.2.2. Biomarker collection
All participants underwent baseline MRI, [C-11]PiB
PET, and LP as described previously [18,19]. A total of 78
additionally underwent a second PiB scan approximately 2
years later. The first visit at which amyloid scans, MRI
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visit 1; the second imaging visit is referred to as follow-up
or visit 2. PiB distribution volume ratio (DVR) maps were
used as the amyloid variable for all voxel-wise analyses. A
composite measurement of global amyloid derived from
eight bilateral regions of interest (ROIs) was calculated for
visit 1 and visit 2 as described previously [20] and is hence-
forth referred to as PiB burden.
CSF measures were selected based on their ability to
detect known pathology in AD including amyloid deposition
(Ab42), neurofibrillary tangles (p-tau), neuronal damage (t-
tau and NFL), and inflammation (MCP-1 and YKL-40).
We also examined the most commonly described CSF ratios
of p-tau/Ab42, t-tau/Ab42, and Ab42/Ab40 as well as more
novel ratios of NFL,MCP-1, and YKL-40 to Ab42. To ensure
that these ratios truly reflect cumulative pathology, we addi-
tionally examined the inverse of Ab42 (1/Ab42) to mimic the
effect of CSF Ab42 in the denominator without a marker of
pathology in the numerator.2.3. Cognitive data measures and collection
At each WRAP visit, participants completed a compre-
hensive neuropsychological battery. To investigate the rela-
tionship between CSF biomarkers and episodic memory
performance, we selected the delayed memory scores from
the Rey auditory verbal learning test (RAVLT) and the
Wechsler memory scale-revised (WMS-R) [21–24]. For
RAVLT, which was initiated at the first wave of WRAP
neuropsychology data collection, one participant had two
time points, 25 had three time points, 52 had four time
points, and 25 had five time points. For WMS-R, which
was initiated at the second wave, 25 participants had two
time points, 52 had three time points, and 25 had four time
points.2.4. Statistical analyses
Separate models were run for each CSF measure unless
otherwise stated. Covariates always include age at LP, sex,
parental family history (FH), and APOE ε4.
For models run in Statistical Package for the Social Sci-
ences (SPSS) 22, significance is inferred at P, .05, adjusted
for multiple comparisons with false discovery rate (FDR)
correction [25]. Regressions were hierarchical such that
the model’s first step includes only covariates and the second
step adds the individual CSF measure. R2 change is calcu-
lated as the difference between the R2 of the first and second
steps of the model. Effect sizes were calculated using Co-
hen’s f2 for hierarchical multiple regression; effect sizes of
0.02, 0.15, and 0.35 are interpreted as small, medium, and
large, respectively. Results are visualized using partial
regression plots, which are scatter plots of residuals from
regressing PiB burden and the CSF variable on all other
predictors.2.4.1. Concurrent CSF measures and amyloid
2.4.1.1. PiB burden
PiB burden at the initial scan was entered as the depen-
dent variable in a multiple regression model in SPSS 22,
and individual CSF measures were entered as the indepen-
dent variable of interest, along with covariates.
To minimize effects of multicollinearity among CSF
measures, a separate model was run for each CSF
analyte or ratio, adjusting for covariates. However, AD is a
multifaceted disease and ratios are only able to capture
two pathologic features. Therefore, we also examined a
comprehensive regression model with all CSF biomarkers
with the exception of p-tau because it was highly correlated
with t-tau (Spearman’s r5 .881). Using baseline PiB burden
as the outcome, we performed hierarchical regression with z-
scores of CSF t-tau, MCP-1, YKL-40, NFL, and Ab42 in
addition to the standard covariates to determine the addi-
tional predictive power of each biomarker to the overall
model. For each of these CSF measures, a model would
include all covariates and four of the five CSF variables as
the first step and then the fifth CSF measure would be added
as the second step. Standardized rather than unstandardized
b-coefficients are reported for easier comparison of contri-
butions of each variable to the model.
2.4.1.2. Regional Ab
A multiple regression framework in statistical parametric
mapping (SPM) 12 (http://www.fil.ion.ucl.ac.uk/spm/) was
used to assess relationships between CSF markers associated
with AD pathology and amyloid in the brain. Baseline PiB
DVR images were entered as the dependent variable, and in-
dividual CSFmeasureswere input as the independent variable
of interest in addition to the standard covariates. Analyses
were restricted to the cerebral gray matter using a template-
based mask. Significance was inferred at the voxel peak-
level when a ,0.05 with multiple comparisons by family-
wise error (FWE) correction and a cluster extent.100voxels.
2.4.2. Baseline CSF measures and longitudinal amyloid
Although there are many ways to approach longitudinal
data analysis with two time points, we chose a standard
approach of regressing a follow-up variable on the baseline
variable and covariates [26,27]. This method statistically
controls for variance in the baseline state, enabling the
interpretation of variables affecting follow-up state indepen-
dent of baseline.
2.4.2.1. PiB burden
PiB burden at visit 2 was entered as the dependent vari-
able in a multiple regression model in SPSS 22. In addition
to the standard set of covariates, we also controlled for PiB
burden at visit 1 and then looked at the effect of the CSF an-
alyte. By controlling for amyloid load at visit 1 and looking
at amyloid load at visit 2 as the outcome, the coefficient on
an individual CSF measure is interpreted as the effect of that
CSF measure on longitudinal amyloid load, controlling
Table 1
Sample characteristics
Demographics Range Mean (SD) or %
Age at LP (years) 49.04–70.96 61.15 (5.58)
Sex (% female) 66%
APOE ε4* (% positive) 38%
FH (% positive) 77%
Education (years) 12–21 16.63 (2.47)
PiB burden Range n Mean (SD)
PiB visit 1 0.995–1.68 104 1.17 (0.15)
PiB visit 2 0.991–1.83 78 1.17 (0.17)
PiB burden change
from visit 1 to visit 2y
20.12 to 0.20 78 0.0047 (0.059)
CSF measures (ng/L)
n PiB visit 1,
n PiB visit 2 Mean (SD)z
Amyloid
Ab42 103, 78 735.91 (205.06)
Ab42/Ab40 104, 78 0.096 (0.018)
1/Ab42 101, 76 0.0014 (0.0004)
Neural injury
T-tau 103, 77 317.50 (112.53)
P-tau 102, 76 43.09 (13.77)
NFL 102, 77 597.21 (185.06)
T-tau/Ab42 100, 75 0.440 (0.191)
P-tau/Ab42 99, 75 0.060 (0.024)
NFL/Ab42 99, 76 0.844 (0.317)
Inflammation
MCP-1 104, 78 558.27 (131.56)
YKL-40 102, 76 139,470.69
(41,248.72)
MCP-1/Ab42 101, 76 0.810 (0.317)
YKL-40/Ab42 99, 74 194.11 (60.91)
Intervals Range Mean (SD)
PiB visit 1 to
visit 2 (months)
21–33 25.47 (2.37)
PiB visit 1 to LP (days) 257 to 68 21.35 (18.32)
PIB visit 1 to NP testing
wave 1 (months)
0–107 70.24 (19.88)
First RAVLT testing (wave 1)
to LP (months)
36–109 70.29 (19.88)
First WMS-R testing (wave 2)
to LP (months)
211 to 58 20.67 (17.04)
Abbreviations: SD, standard deviation; LP, lumbar puncture; APOE ε4,
possession of apolipoprotein E ε4 allele; FH, parental family history; PiB,
Pittsburgh compound B amyloid imaging; CSF, cerebrospinal fluid; Ab,
beta-amyloid; t-tau, total tau; p-tau, phosphorylated-tau; NFL, neurofila-
ment light protein; MCP-1, monocyte chemoattractant protein 1; YKL-40,
chitinase-3–like protein; NP, neuropsychology; RAVLT, Rey auditory ver-
bal learning test; WMS-R, Wechsler memory scale-revised.
*APOE ε4 allele breakdown: 38% APOE ε4; n5 13 ε2/ε3, n5 52 ε3/ε3,
n 5 3 ε2/ε4, n 5 35 ε3/ε4, and n 5 1 ε4/ε4.
yPiB burden change is displayed for descriptive purposes only, it was not
used in any statistical analyses.
zCSF was only collected once, mean and SD values are for all subjects at
PiB visit 1.
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2 years apart (mean 5 25.47 months; standard
deviation 5 2.37 months; range 5 21–33 months) because
the study was designed to keep this interval uniform, and
variation was relatively symmetrical, it was not included
as a covariate in the regression models.
We repeated the hierarchical regression model, which
included the five CSF measures (t-tau, MCP-1, YKL-40,
NFL, and Ab42) simultaneously, for longitudinal PiB
burden. Each model included the standard covariates as
well as baseline PiB burden, and four of the five CSF vari-
ables as the first step; then the fifth CSF measure was added
as the second step. Standardized rather than unstandardized
b-coefficients are reported for easier comparison of contri-
butions of each variable to the model.
2.4.2.2. Regional Ab
To gain spatial resolution on findings from the mentioned
analyses, regressions using biological parametric mapping, an
SPM5 toolbox for multimodal image analysis based on a
voxel-wise use of the general linear model [28], were per-
formedonCSFmeasures thatwere associatedwith longitudinal
PiB burden. The PiB DVR scan from the second visit was the
dependent variable and the PiB DVR scan from the first visit
was used as an imagingcovariate in addition tofivenonimaging
covariates: age, sex, APOE ε4, FH, and CSF biomarker level.
Because visit 1 amyloid burden was such a strong predictor
of visit 2 amyloid burden, we chose a more moderate threshold
for the resultant longitudinal statistical maps of a ,0.001
(uncorrected) together with a cluster extent.250 voxels; how-
ever, our primary inference was still at the peak voxel where
significance was again evaluated at a(FWE),0.05.
2.4.3. CSF measures and cognitive decline
Linear mixed-effects regression was used to model the ef-
fect of the CSF biomarkers that predicted longitudinal Ab
accumulation on longitudinal cognitive decline measured by
tests of delayed recall. First, unconditional means models ad-
justing for random effects were examined using unstructured
covariance structure.Next, conditionalmodelswere runwhich
included significant random effects plus fixed effects of sex,
APOE ε4, FH, interval between first cognitive evaluation
and LP (months), literacy (time 1 Wide Range Achievement
Test III reading scores), CSF biomarker level, time (age at
eachvisit), and the interaction of time!CSFmeasure (slope).
3. Results
3.1. Sample characteristics
Sample characteristics are summarized in Table 1.
3.2. Concurrent CSF measures and amyloid3.2.1. PiB burden
CSF t-tau, Ab42, Ab42/Ab40, 1/Ab42, t-tau/Ab42, p-tau/
Ab42, NFL/Ab42, MCP-1/Ab42, and YKL-40/Ab42 allsignificantly predicted baseline PiB burden at P(FDR)
,.05 (Supplementary Table 2, Fig. 1). Additionally, p-tau
(P 5 .04) was significant at an uncorrected threshold of
P , .05. Ab42/Ab40, 1/Ab42, t-tau/Ab42, and p-tau/Ab42
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and YKL-40/Ab42 had medium effect sizes; and t-tau and
p-tau had small effect sizes.
When CSF measures of amyloid, neural injury, and
inflammation were simultaneously included as predictors
in the model, only t-tau and Ab42 significantly accounted
for variance in baseline PiB burden. Inclusion of CSF Ab42
(R2 change 5 0.229; f2 5 0.495) and t-tau (R2
change 5 0.104; f2 5 0.225) significantly improved the
model. Ab42 (standard b 5 20.582, P , .001) and t-tau
(standard b5 0.385, P, .001) were the strongest predictors
of baseline brain amyloid burden.
3.2.2. Regional Ab
CSF Ab42, Ab42/Ab40, and all ratios of individual CSF
markers to CSF Ab42 were consistently related to a spatial
pattern of amyloid in the brain in regions commonly
affected in AD including posterior cingulate, lateral parie-
tal cortex, precuneus, and medial prefrontal cortex (Fig. 2).
Supplementary Table 3 provides statistical details and
anatomic locations for the peaks that survived P(FWE)
,.05. Although tau alone did not survive FWE at the
voxel-level, tau/Ab42 showed a significant positive rela-
tionship with amyloid burden. These data support a model
where amyloid burden is more severe in the presence of
neurofibrillary pathology. The statistical map of the inverse
of Ab42 (1/Ab42) shows a significant relationship that is
consistent but not identical with the overall pattern of other
CSF measures.3.3. Baseline CSF measures and longitudinal amyloid3.3.1. PiB burden
T-tau/Ab42, p-tau/Ab42, and NFL/Ab42 were significantly
associated with PiB burden at visit 2 at P(FDR) ,.05
(Supplementary Table 4, Fig. 3). Ab42/Ab40 (P 5 .017)
and MCP-1/Ab42 (P 5 .03) were additionally associated
with PiB burden at visit 2 at P(uncorrected),.05. All results
were in the expected direction (CSF/Ab42 were positive,
whereas Ab42 and Ab42/Ab40 were negative). These results
suggest that a composite CSF measurement, here in the
form of a ratio, which is sensitive to both amyloid (Ab42)
and neural injury (tau, p-tau, or NFL) or inflammation
(MCP-1), predicts amyloid deposition over time. All f2 effect
sizes for CSF markers were small because visit 1 PiB burden
is a very strong predictor of visit 2 PiB burden. T-tau/Ab42
and p-tau/Ab42 had the largest effect sizes (f
2 .0.12) of
the CSF biomarkers.
When CSF measures of amyloid, neural injury, and
inflammation were simultaneously included as predictors
in the longitudinal model, only t-tau significantly accounted
for variance in amyloid accumulation (R2 change 5 0.007;
f2 5 0.08). Besides amyloid load at visit 1 (standard
b 5 0.794, P , .001), Ab42 (standard b 5 20.107,P 5 .053) and t-tau (standard b 5 0.113, P 5 .034)
were the strongest predictors of longitudinal amyloid
accumulation.
3.3.2. Regional Ab
T-tau/Ab42, p-tau/Ab42, NFL/Ab42, and MCP-1/Ab42
were positively associated and Ab42/Ab40 was negatively
associated with longitudinal amyloid deposition in the eight
ROIs (Fig. 4). Supplementary Table 5 provides statistical de-
tails and anatomic locations for the peaks that survived
P(FWE) ,.05. Ratios were primarily associated with amy-
loid increases in the frontal and lateral parietal and temporal
lobes, and p-tau/Ab42 and MCP-1/Ab42 were additionally
associated with amyloid increases in the precuneus.3.4. CSF measures and cognitive decline
A significant relationship between the CSF ratios which
predicted longitudinal Ab accumulation (CSF Ab42/Ab40,
t-tau/Ab42, p-tau/Ab42, NFL/Ab42, and MCP-1/Ab42) and
slope of cognitive decline was not detected.4. Discussion
The etiology of AD involves multiple pathologic pro-
cesses occurring decades before disease onset, with the
two primary forms of pathology consisting of amyloid pla-
ques and neurofibrillary tangles. AD is also associated
with inflammation [29] and changes in white matter struc-
tural integrity [30]. The aim of the present study was to
better characterize early coincident preclinical changes
by examining the relationship between CSF biomarkers
covering different aspects of AD neuropathology and
PET-PiB amyloid deposition in a relatively younger cogni-
tively healthy adult sample. Our overarching hypothesis,
that CSF markers of neural injury would predict both
baseline and longitudinal Ab burden, was supported.
CSF ratios to Ab42 were spatially related to amyloid depo-
sition in regions commonly affected in AD at baseline,
and CSF ratios of tau to Ab42 were related to an increase
in global Ab load and to a spatial pattern of Ab in the
brain in AD-sensitive ROIs longitudinally assessed over
a 2-year time span. Although an array of CSF biomarkers
have been shown to be related to amyloid longitudinally in
a similar cohort [31], this is the first known study to pro-
vide spatial specificity with voxel-wise analyses, and to
investigate novel ratios reflecting simultaneous gliosis
and Ab deposition.
Voxel-wise analyses showed CSF markers had a highly
conserved relationship to amyloid within regions commonly
labeled as the default mode network (DMN) including
lateral parietal cortex, precuneus, and medial prefrontal cor-
tex. It has been suggested that susceptibility to amyloid
deposition in these regions may be due to high activity or
metabolism [32–34] and relatively greater extent of
Fig. 1. Partial regression plots of CSFmeasures and baseline PiB burden. Y-axis: DVR of baseline PiB burden adjusted for all other predictors in the model (age,
sex, APOE ε4, and FH). X-axis: CSF measure adjusted for all other predictors in the model. 95% confidence intervals for the regression line are displayed.
Abbreviations: PiB, Pittsburgh compound B; CSF, cerebrospinal fluid; DVR, distribution volume ratio; Ab, beta-amyloid; NFL, neurofilament light protein;
t-tau, total tau; p-tau, phosphorylated-tau; MCP-1, monocyte chemoattractant protein 1; YKL-40, chitinase-3–like protein; FH, parental family history.
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Fig. 2. Heat maps of T-statistics for voxel-wise regressions of baseline CSF measures on baseline PiB images rendered onto a template brain for (A) Ab42, (B)
Ab42/Ab40, (C) 1/Ab42, (D) p-tau/Ab42, (E) t-tau/Ab42, (F) NFL/Ab42, (G)MCP-1/Ab42, and (H) YKL-40/Ab42. The negative contrast is displayed for Ab42 and
Ab42/Ab40, and the positive contrast is displayed for all other ratios. Color bars representing t-statistics from 0 to 7 are on the right. All voxels are significant at
P(FWE),.05. Abbreviations: CSF, cerebrospinal fluid; Ab, beta-amyloid; PiB, Pittsburgh compound B; p-tau, phosphorylated-tau; t-tau, total tau; NFL, neuro-
filament light protein; MCP-1, monocyte chemoattractant protein 1; FWE, family-wise error; YKL-40, chitinase-3–like protein.
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Fig. 3. Partial regression plots of CSF measures and follow-up PiB burden. Y-axis: DVR of follow-up PiB burden adjusted for all other predictors in the model
(age, sex, APOE ε4, FH, and baseline PiB burden). X-axis: CSF measure adjusted for all other predictors in the model. 95% confidence intervals for the regres-
sion line are displayed. Abbreviations: CSF, cerebrospinal fluid; PiB, Pittsburgh compound B; DVR, distribution volume ratio; Ab, beta-amyloid; p-tau,
phosphorylated-tau; t-tau, total tau; NFL, neurofilament light protein; MCP-1, monocyte chemoattractant protein 1; FH, parental family history.
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(2005) found convergence of five different in vivo imaging
methods on the DMN in young adults and older adults
with AD, postulating that lifetime cerebral metabolism in
the DMN predisposes these cortical regions to AD-related
changes including amyloid deposition, metabolic disruption,
and atrophy.
CSF ratios with Ab42 were consistently significantly
associated with PiB amyloid burden in the brain at baseline
and 2-year follow-up. Correspondingly, previous literature
has demonstrated that Ab42/Ab40 is decreased in AD[5,38] and improves accuracy of distinguishing prodromal
AD and dementia compared with Ab42 alone [39]. The ratio
has been suggested to normalize the Ab42 concentration to a
measure of overall amyloidogenic processing by amyloid
precursor protein, making it possible to detect low Ab42 in
high Ab producers and vice versa [40]. Similarly, studies
have shown that combinations of tau and Ab42 improve
sensitivity and specificity [5,41,42], predict subjective
cognitive decline [43], and predict conversion from a clinical
dementia rating of 0 (cognitively normal) to 1 (mild demen-
tia; [44]) and from mild cognitive impairment to AD [45].
Fig. 4. Heat maps of T-statistics for voxel-wise BPM regressions of CSFmeasures on longitudinal PiB rendered onto a template brain for (A) Ab42/Ab40, (B) p-
tau/Ab42, (C) t-tau/Ab42, (D) NFL/Ab42, and (E) MCP-1/Ab42. The negative contrast is displayed for Ab42 and Ab42/Ab40, and the positive contrasts are dis-
played for all other ratios. BPM statistical maps are thresholded at P, .001 with cluster extent.250 voxels. All clusters are significant at P(FWE),.05. Color
bars representing t-values from 0 to 6 are on the right. Abbreviations: BPM, biological parametric mapping; CSF, cerebrospinal fluid; PiB, Pittsburgh compound
B; Ab, beta-amyloid; FWE, family-wise error; p-tau, phosphorylated-tau; t-tau, total tau; NFL, neurofilament light protein; MCP-1, monocyte chemoattractant
protein 1.
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loid effects but also more subtle disease-relevant tau
changes, with simultaneous pathology more indicative of
disease. This is particularly interesting in light of recent
and compelling evidence showing that tau increases Ab pro-
duction [13].
The NFL/Ab42 findings further support a theory of coin-
cident axonal degeneration and amyloid pathology. Interest-
ingly, the ratio of the inflammatory marker of MCP-1 to
Ab42 was also related to both baseline and longitudinal am-
yloid, but YKL-40/Ab42 only predicted baseline amyloid.MCP-1 has been found near amyloid plaques [46], is upregu-
lated in CSF of AD patients [47], and predicts future conver-
sion to AD and the rate of cognitive decline [48]. Although
these findings and ours suggest a role for coincident Ab and
microglial/inflammatory processes in AD pathogenesis,
other studies have shown mixed results for the diagnostic
value of these CSF markers [49]. More studies are needed
to validate these CSF analytes, and their ratios to Ab42, as
AD biomarkers.
Our results indicated that 1/Ab42 was a strong predictor of
baseline Ab in a consistent but not identical pattern to other
A.M. Racine et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 2 (2016) 27-3836CSF measures. This suggests not only that Ab42 in the de-
nominator is not solely driving results but also that 1/Ab42
may even be more sensitive to amyloid in the brain than
Ab42 alone, possibly because the inverse transformation cor-
rects for positive skewness. However, 1/Ab42 did not survive
significance thresholds in the longitudinal frameworks, sug-
gesting that ratios with markers of neural injury truly reflect
cumulative pathology rather than a mathematical phenome-
non. Effect sizes further support the theory that ratios provide
more information than 1/Ab42 alone. For baseline analyses,
t-tau/Ab42 and p-tau/Ab42 had larger effect sizes than
1/Ab42 (Supplementary Table 2). Coincident markers seem
to be even more relevant for predicting longitudinal amyloid
accumulation, which showed larger effect sizes for all ratios
with Ab42 except YKL-40/Ab42 compared with 1/Ab42,
which was not significant (Supplementary Table 4). There-
fore, at a single time point, CSFAb42 (or 1/Ab42) may be suf-
ficient to detect brain Ab, but CSF ratios indicative of
simultaneous pathology predict progressive accumulation
over time, which is a stronger indicator of disease progression
than stable brain amyloid levels. However, a supplemental
analysis suggests that although t-tau/Ab42 and p-tau/Ab42 ac-
count for unique variance above and beyond 1/Ab42, the story
is less clear for MCP-1/Ab42 and NFL/Ab42 (Supplementary
Table 6). These remain important biomarkers to investigate,
and may prove to be better predictors of other AD-relevant
outcomes, or more informative at more advanced ages and
stages of the preclinical AD time course. This will be ascer-
tained with a future study.
The majority of our baseline and longitudinal analyses
indicate that CSF measures of amyloid alone but not tau
alone corresponded with amyloid load in the brain, consis-
tent with previous findings [50]. This is likely because our
sample is relatively young and, thus, may show considerable
amyloid pathology while only beginning to show changes in
tau. Consistent with this theory, Buchhave et al. [51] (2009)
found that among AD patients, Ab42 levels did not change
over time but tau increased 16% over 2 years, with higher
levels associated with faster conversion. This suggests that
Ab42 levels increase earlier in the disease stage and then
plateau, whereas tau biomarkers may increase gradually
closer to symptom onset [45]. Similarly, findings fromKanai
et al. [52] suggest that although CSF Ab42 and Ab42/Ab40
may make the most significant changes at early AD stages,
CSF tau likely increases with clinical progression of demen-
tia. The data here suggest that at the earliest stages of
increasing tau pathology—likely at an intermediary stage
of amyloid accumulation—tau may interact to accelerate
brain amyloid accumulation. The comprehensive model
with all CSF biomarkers highlights the important contribu-
tion of tau to preclinical amyloid accumulation. This finding
that tau significantly contributes to a model when Ab42 is
also included in the model in addition to findings that tau/
Ab42 but not tau alone was significant in voxel-wise models
further corroborates our theory that tau’s impact on AD path-
ogenesis is dependent on the presence of amyloid.Although there are likely subtle cognitive changes occur-
ring during the preclinical time period [1,2,53], we did not
find a significant association between CSF biomarkers and
slopes of episodic memory. However, because of the
relatively young age and cognitive health of our sample,
associations between CSF biomarkers and cognitive
decline are likely to be subtle. These findings do not
preclude the likely possibility that CSF ratios are related to
preclinical cognitive decline. Furthermore, others have
found that change in CSF levels may be more closely
related to cognition [31,54]. Longitudinal CSF collection
and ongoing neuropsychological testing is underway in
this cohort and will be critical to understanding the
relationship of CSF changes over time to disease
progression, cognitive decline, and an interacting cascade
between tau and amyloid.
There are limitations to our study that deserve
mentioning. First, CSF from LP is only an indirect measure
of pathology; however, it is a common clinical and research
technique that is currently much less expensive and more
widely available than PET imaging. Second, although this
cohort is enriched for risk factors for AD, our sample’s rela-
tively younger age and lack of significant clinical symptoms
restrict our clinical interpretation of the results. Third, the
correlational design of this study prevents us from
describing causal mechanisms between CSF analytes and
AD pathology or symptoms. Fourth, serial CSF was not
available, further preventing this study from ascertaining
whether amyloid and tau are interacting in a reciprocal pos-
itive feedback loop, as recent work suggests [13]. Fifth, CSF
analytes and ratios were correlated, making interpretation of
a model with multiple CSF analytes less interpretable, even
though neural injury, inflammation, and amyloid likely
interact to impact amyloid accumulation. Although they
are interpreted with this caution, the findings from the cumu-
lative model suggest that tau and Ab42 are the strongest CSF
predictors and statistically improve modeling of amyloid
accumulation, and normal tolerance and variance inflation
factors suggest that each variable was contributing unique
variance.
This study adds important breadth to the investigation of
biomarkers for AD by first, examining a spread of bio-
markers spanning neural injury, inflammation, and gliosis
in addition to the traditional measures of tau and Ab42; sec-
ond, recruiting participants who are enriched for AD risk
factors but are still in late-middle age and are cognitively
normal; and third, longitudinally assessing both brain amy-
loid and cognitive decline. Follow-up longitudinal studies
investigating clinical outcomes are necessary to determine
the diagnostic accuracy of these biomarkers.Acknowledgments
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1. Systematic review: The authors reviewed and appro-
priately cited the literature using traditional online
sources and data presented at relevant conferences.
There is estimable analysis on Alzheimer’s disease
(AD) fluid and imaging biomarkers in older adults
who are normal or cognitively impaired, but consid-
erably less information is available regarding the
important preclinical late-midlife time frame.
2. Interpretation: These findings support a theory
whereby presence of b-amyloid (Ab) in addition to
other pathologic features of AD including neural
injury, neurofibrillary tangles, and gliosis predict am-
yloid accumulation in the preclinical time frame.
3. Future directions: Longitudinal analysis of bio-
markers is critical for understanding their utility,
especially when collection and analysis begins in
the preclinical time frame which by definition and
design implies a lack of clinical outcomes initially.
This work, therefore, sets the groundwork for base-
line and earliest change, and future research will
investigate clinical end points, longitudinally
measured cerebrospinal fluid biomarkers, and longi-
tudinal multimodal imaging.References
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